CRISPR technologies hold vast potential for therapeutic gene editing, however large structural variations often arise, posing an underappreciated safety concern. Here, the authors review emerging evidence of aberrant chromosomal abnormalities and discuss strategies to improve safety outcomes.
- Clotilde Aussel
- Toni Cathomen
- Carla Fuster-García
